<DOC>
	<DOCNO>NCT01422213</DOCNO>
	<brief_summary>Major Depressive Disorder ( MDD ) severe common psychiatric disorder . Although MDD primarily involve mood disturbance , patient also usually present alteration cognitive function ( attention , memory , executive functioning psychomotor speed ) . Even though antidepressant suggest literature potentially improve cognitive dysfunction patient MDD degree , lack adequate well-controlled study investigate effect . This study evaluate efficacy , safety tolerability new antidepressant Vortioxetine versus placebo cognitive dysfunction adult patient MDD .</brief_summary>
	<brief_title>Efficacy Study Vortioxetine Cognitive Dysfunction Adult Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>The patient inpatient psychiatric hospital outpatient psychiatric setting time study entry . The patient diagnose recurrent MDD accord DSMIVTR™ criterion ( classification code 296.3x ) . The current Major Depressive Episode ( MDE ) confirm use Mini International Neuropsychiatric Interview ( MINI ) . The patient receive prescribed treatment previous episode depression . The patient MADRS total score ≥26 . The report duration current MDE least 3 month . The patient score ≥70 DSST ( number correct symbol ) , ≥42 RAVLT ( learn ) ≥14 RAVLT ( memory ) Baseline Visit . The patient current Axis I disorder ( DSMIVTR™ criterion ) MDD , confirm use MINI . The patient current diagnosis history manic hypomanic episode , schizophrenia psychotic disorder , include major depression psychotic feature . The patient suffers personality disorder , mental retardation , pervasive development disorder , attentiondeficit/hyperactivity disorder , organic mental disorder , mental disorder due general medical condition ( DSMIVTR™ criterion ) . The patient physical , cognitive , language impairment severity adversely affect validity data derive neuropsychological test . The patient diagnose read disability ( dyslexia ) . The patient significant risk suicide score ≥5 Item 10 ( suicidal thought ) MADRS , attempt suicide &lt; 6 month prior Screening Visit . The patient receive electroconvulsive therapy &lt; 6 month prior Screening Visit . The current depressive symptom consider investigator resistant 2 adequate antidepressant treatment least 6 week duration recommend dose . The patient history moderate severe head trauma ( example , loss consciousness 1 hour ) neurological disorder systemic medical disease , opinion investigator , likely affect central nervous system function . The patient history cancer , basal cell Stage 1 squamous cell carcinoma skin , remission &gt; 5 year prior first drug dose . The patient clinically significant unstable illness , example : cardiovascular disease seizure disorder encephalopathy congestive heart failure cardiac hypertrophy arrhythmia bradycardia ( pulse &lt; 50 bpm ) respiratory disease hepatic impairment renal insufficiency metabolic disorder endocrinological disorder gastrointestinal disorder haematological disorder infectious disorder clinically significant immunological condition dermatological disorder venereal disease The patient , Screening Visit , abnormal ECG , investigator 's opinion , clinically significant . The patient , investigator 's opinion , unlikely comply protocol unsuitable reason . The patient previously expose Vortioxetine . Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>MDD</keyword>
	<keyword>Cognitive dysfunction</keyword>
</DOC>